Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Gilead, MicroDose collaborate on RSV treatment
June 2011
SHARING OPTIONS:

FOSTER CITY, Calif.Gilead and MicroDose Therapeutx have entered into a license and collaboration agreement for the development of a treatment for respiratory syncytial virus (RSV). The two companies will work together to develop and commercialize MicroDose's MDT-637, an inhalable small-molecule antiviral fusion inhibitor for the treatment of RSV. According to MicroDose, preclinical testing has proved the inhibitor can block RSV infection. Under the agreement, Gilead will make an upfront payment and support the compound's development through Phase IIa clinical trials, after which Gilead will assume full responsibility for subsequent trials. Anand Gumaste, president and CEO of MicroDose, says the collaboration "provides a strong validation of the potential for MDT-637 to become an important therapeutic advance for those affected by RSV infection."


Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.